Roundtables: A Conversation With the Creator of AI

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-09T02:00:36.663Z • Permanent link

Google's DeepMind division, led by Demis Hassabis, has been at the forefront of AI research for over two decades. Their latest endeavor, the development of AI-designed viruses, has sent shockwaves throughout the scientific community. According to reports, DeepMind's team has been working on creating custom-made viruses that can evade current detection methods, raising concerns about the potential misuse of this technology.

The project, code-named "Simons," was initiated in 2019 and has since attracted significant attention from researchers and policymakers. The team, consisting of experts from various fields, including computer science, biology, and mathematics, has been exploring the possibilities of using AI to design viruses that can target specific cells or tissues. According to a recent report by the Financial Times, the team has made significant breakthroughs in this area, with some of their creations showing a high degree of efficacy in laboratory tests.

Notably, the Simons project has been shrouded in secrecy, with limited information available about the project's scope and goals. However, sources close to the project have revealed that the team has been working closely with pharmaceutical companies, such as GlaxoSmithKline and Pfizer, to explore the potential applications of their research. While the exact nature of these collaborations remains unclear, experts warn that the development of AI-designed viruses could have far-reaching implications for public health and the global economy.

The emergence of AI-designed viruses has significant implications for the biotechnology industry, with companies like Biogen and Moderna already investing heavily in AI-powered research. According to a report by the market research firm, Deloitte, the global biotech industry is expected to reach $1.5 trillion by 2025, with AI playing a key role in driving this growth. However, the development of AI-designed viruses also raises concerns about the potential for misuse, particularly in the context of bioterrorism.

The Simons project has also sparked concerns among researchers, who worry that the development of custom-made viruses could undermine the integrity of scientific research. "This is a Pandora's box," said Dr. Francis Collins, the director of the National Institutes of Health, in a recent interview. "If we allow the development of custom-made viruses, we risk creating a situation where scientists can design viruses that can evade current detection methods, which could have catastrophic consequences for public health.

The development of AI-designed viruses is part of a larger trend in the biotech industry, where researchers are increasingly using machine learning and other AI techniques to accelerate the discovery of new treatments and therapies. However, this trend has also raised concerns about the ethics of using AI in biotech research, particularly in the context of gene editing and synthetic biology.